Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 297

1.

Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST.

Miao R, Wang H, Jacobson A, Lietz AP, Choy E, Raskin KA, Schwab JH, Deshpande V, Nielsen GP, DeLaney TF, Cote GM, Hornicek FJ, Chen YE.

Radiother Oncol. 2019 May 9;137:61-70. doi: 10.1016/j.radonc.2019.03.015. [Epub ahead of print]

PMID:
31078939
2.

Advances in immune checkpoint inhibitors for bone sarcoma therapy.

Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z.

J Bone Oncol. 2019 Jan 29;15:100221. doi: 10.1016/j.jbo.2019.100221. eCollection 2019 Apr. Review.

3.

Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.

Houdek MT, Rose PS, Hevesi M, Schwab JH, Griffin AM, Healey JH, Petersen IA, DeLaney TF, Chung PW, Yaszemski MJ, Wunder JS, Hornicek FJ, Boland PJ, Sim FH, Ferguson PC; Other Members of the Sacral Tumor Society.

J Surg Oncol. 2019 Jun;119(7):856-863. doi: 10.1002/jso.25399. Epub 2019 Feb 7.

PMID:
30734292
4.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

FASEB J. 2019 May;33(5):5990-6000. doi: 10.1096/fj.201801789RR. Epub 2019 Feb 6.

PMID:
30726104
5.

Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.

Tang F, Min L, Seebacher NA, Li X, Zhou Y, Hornicek FJ, Wei Y, Tu C, Duan Z.

J Orthop Res. 2019 Mar;37(3):789-798. doi: 10.1002/jor.24227. Epub 2019 Feb 12.

PMID:
30667081
6.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.

Ma H, Seebacher NA, Hornicek FJ, Duan Z.

EBioMedicine. 2019 Jan;39:182-193. doi: 10.1016/j.ebiom.2018.12.022. Epub 2018 Dec 20.

7.

Current treatment strategy for newly diagnosed chordoma of the mobile spine and sacrum: results of an international survey.

Dea N, Fisher CG, Reynolds JJ, Schwab JH, Rhines LD, Gokaslan ZL, Bettegowda C, Sahgal A, Lazáry Á, Luzzati A, Boriani S, Gasbarrini A, Laufer I, Charest-Morin R, Wei F, Teixeira W, Germscheid NM, Hornicek FJ, DeLaney TF, Shin JH; AOSpine Knowledge Forum Tumor.

J Neurosurg Spine. 2018 Oct 19;30(1):119-125. doi: 10.3171/2018.6.SPINE18362.

PMID:
30497218
8.

Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.

Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z.

J Orthop Res. 2019 Feb;37(2):510-521. doi: 10.1002/jor.24189. Epub 2019 Jan 3.

PMID:
30488489
9.

Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.

van Wulfften Palthe ODR, Tromp I, Ferreira A, Fiore A, Bramer JAM, van Dijk NC, DeLaney TF, Schwab JH, Hornicek FJ.

Spine J. 2019 May;19(5):869-879. doi: 10.1016/j.spinee.2018.11.002. Epub 2018 Nov 14.

PMID:
30445184
10.

RNA sequencing (RNA-Seq) and its application in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

Gynecol Oncol. 2019 Jan;152(1):194-201. doi: 10.1016/j.ygyno.2018.10.002. Epub 2018 Oct 5. Review.

PMID:
30297273
11.

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.

Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z.

Cancer Lett. 2018 Dec 28;439:66-77. doi: 10.1016/j.canlet.2018.09.012. Epub 2018 Sep 14.

PMID:
30223067
12.

From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.

Dean DC, Shen S, Hornicek FJ, Duan Z.

Cancer Metastasis Rev. 2018 Dec;37(4):719-731. doi: 10.1007/s10555-018-9763-8. Review.

PMID:
30167827
13.

Henry J. Mankin: A Trailblazer in Skeletal Pathology Research.

Sun CM, Schwab JH, Hornicek FJ.

Spine (Phila Pa 1976). 2018 Jun 8. doi: 10.1097/BRS.0000000000002730. [Epub ahead of print]

PMID:
29889796
14.

Complications and reoperations after surgery for 647 patients with spine metastatic disease.

Paulino Pereira NR, Ogink PT, Groot OQ, Ferrone ML, Hornicek FJ, van Dijk CN, Bramer JAM, Schwab JH.

Spine J. 2019 Jan;19(1):144-156. doi: 10.1016/j.spinee.2018.05.037. Epub 2018 Jun 1.

PMID:
29864546
15.

Lower Extremity Megaprostheses in Orthopaedic Oncology.

Lozano Calderón SA, Kuechle J, Raskin KA, Hornicek FJ.

J Am Acad Orthop Surg. 2018 Jun 15;26(12):e249-e257. doi: 10.5435/JAAOS-D-16-00218.

PMID:
29781818
16.

Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.

Wang J, Garbutt C, Ma H, Gao P, Hornicek FJ, Kan Q, Shi H, Duan Z.

Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.

PMID:
29699801
17.

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Liu T, Yan Z, Liu Y, Choy E, Hornicek FJ, Mankin H, Duan Z.

Cell Physiol Biochem. 2018;46(3):1218-1230. doi: 10.1159/000489072. Epub 2018 Apr 16.

18.

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.

Li X, Seebacher NA, Garbutt C, Ma H, Gao P, Xiao T, Hornicek FJ, Duan Z.

Cell Death Dis. 2018 May 1;9(5):446. doi: 10.1038/s41419-018-0474-4.

19.

Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma.

Ma H, Li X, Wang J, Hornicek FJ, Garbutt CC, Chang X, Duan Z.

Oncology. 2018;95(1):52-60. doi: 10.1159/000487437. Epub 2018 Apr 4.

20.

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.

Chen H, Shen J, Choy E, Hornicek FJ, Shan A, Duan Z.

Oncotarget. 2017 Nov 28;9(17):13154-13166. doi: 10.18632/oncotarget.22743. eCollection 2018 Mar 2.

Supplemental Content

Loading ...
Support Center